MAY 16 2005
/ .
ko fefoe fp :
e e
e
@ e
Asclepien’
Asclepion Laser Technologies GmbH + Géschwitzer Str. 51-52 « D-07745 Jena Laser Technol og ies
510(k) SUMMARY
ASCLEPION LASER TECHNOLOGIES GmbH
MeDioStar XT Laser System
This 510(k) summary of safety and effectiveness for the Asclepion Laser Technologies
GmbH MeDioStar XT Laser System is submitted in accordance with the requirements of 21
CFR 907.92 and follows Office of Device Evaluation Guidance concerning the organization
and content of a 510(k) summary.
Applicant: ASCLEPION LASER TECHNOLOGIES GmbH
Goeschwitzer Str. 51-52
07745 Jena, Germany
Contact Person: Mr Reinhard Thieme
Quality Assurance and
International Regulatory Affairs
. Phone: +49 3641 220 211
Fax: +49 3641 220 322
e-mail: reinhard.thieme@asclepion.com
Preparation Date: March 23, 2005
Device Name: MeDioStar XT Laser System
Common Name: MeDioStar XT
Classification Name: Instrument, surgical, powered, laser
79-GEX
21 CFR 878.481
Equivalent Device: MeDioStar H Laser Sytsem
(with and without skin cooling system)
Device Description: MeDioStar XT Laser System is a pulsed diode laser with a
wavelength of 808um. it consists a laser enclosure and optic
delivery system (fiber bundle and handpiece). Clas 87

k6 fo 700 “ly

Intended Use: The MeDioStar XT Laser System is intended to remove
unwanted body hair and vascular lesions.

Comparison to: The MeDioStar XT Laser System is substantially equivalent to
the MeDioStar H Laser System (with and without skin cooling),
with the same principles of operation, the same wavelength and
essentially the same power range as the predicate device for the
same indications for uses.

Nonclinical

Performance Data: None

Clinical

Performance Data: None

Conclusion: The MeDioStar XT Laser System is another safe and effective
device for the removal of unwanted body hair and the treatment
of vascular lesions.

Additional Information: None

020088

é DEPARTMENT OF HEALTH & HUMAN SERVICES Public Health Service
%, rn
one Food and Drug Administration
9200 Corporate Boulevard
MAY ] 6 2005 Rockville MD 20850
Mr. Reinhard Thieme
Quality Assurance and International Regulatory Affairs
Asclepion Laser Technologies GmbH
Goeschwitzerstrasse 51-52
Jena, Germany 07745
Re: K050900
Trade/Device Name: MeDioStar XT Laser System
Regulation Number: 21 CFR 878.4810 .
Regulation Name: Laser surgical instrument for use in general and plastic surgery and in
dermatology
Regulatory Class: II
Product Code: GEX
Dated: April 26, 2005
Received: April 28, 2005
Dear Mr. Thieme:
We have reviewed your Section 510(k) premarket notification of intent to market the device
referenced above and have determined the device is substantially equivalent (for the indications
for use stated in the enclosure) to legally marketed predicate devices marketed in interstate
commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to
devices that have been reclassified in accordance with the provisions of the Federal Food, Drug,
and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA).
You may, therefore, market the device, subject to the general controls provisions of the Act. The
general controls provisions of the Act include requirements for annual registration, listing of
devices, good manufacturing practice, labeling, and prohibitions against misbranding and
adulteration.
If your device is classified (see above) into either class II (Special Controls) or class II] (PMA),
it may be subject to such additional controls. Existing major regulations affecting your device
can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA
may publish further announcements concerning your device in the Federal Register.
Please be advised that FDA’s issuance of a substantial equivalence determination does not mean
that FDA has made a determination that your device complies with other requirements of the Act
or any Federal statutes and regulations administered by other Federal agencies. You must
comply with all the Act’s requirements, including, but not limited to: registration and listing (21
CFR Part 807); labeling (21 CFR Part 801); good manufacturing practice requirements as set
forth in the quality systems (QS) regulation (21 CFR Part 820); and if applicable, the electronic
product radiation contro] provisions (Sections 531-542 of the Act); 21 CFR 1000-1050.

Page 2 — Mr. Reinhard Thieme ‘
This letter will allow you to begin marketing your device as described in your Section 510(k)
premarket notification. The FDA finding of substantial equivalence of your device to a legally
marketed predicate device results in a classification for your device and thus, permits your
device to proceed to the market.
If you desire specific advice for your device on our labeling regulation (21 CFR Part 801), please
contact the Office of Compliance at (240) 276-0115. Also, please note the regulation entitled,
"Misbranding by reference to premarket notification” (21CFR Part 807.97). You may obtain
other general information on your responsibilities under the Act from the Division of Small
Manufacturers, International and Consumer Assistance at its toll-free number (800) 638-2041 or
(301) 443-6597 or at its Internet address. http://www.fda.gov/cdrh/industry/support/index.html.

Sincerely yours,

/-Miriam C. Provost, Ph.D.
Acting Director
Division of General, Restorative
and Neurological Devices
Office of Device Evaluation
Center for Devices and
Radiological Health
Enclosure

INDICATIONS FOR USE STATEMENT
510(k) Number (if known): _K4 3° %60
, Device Name: MeDioStar XT Laser System
Indications for Use:
The MeDioStar XT Laser System is intended to remove unwanted body hair
and vascular lesions. Prescription Use x AND/OR Over-The-Counter Use
(Part 21 CFR 801 Subpart D) (21 CFR 801 Subpart C)
(PLEASE DO NOT WRITE BELOW THIS LINE-CONTINUE ON ANOTHER PAGE
OF NEEDED)
atm ant
Concurrence of CDRH, Office of Device Evaluation (ODE)
ou gir wp a
‘ision of General, Restorative
“Tov=tinetaal Devices
/ Ko So 6b
O209°9
Page 1 of 1

